Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity

被引：0
|
作者：
Huck, C. [1 ]
Wegert, V. [1 ]
Schmid, C. [1 ]
Dunn, B. [2 ]
Smith, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
[2] Novartis Inst Funct Genom Inc, San Diego, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P401
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [31] Anti-CD20 therapy ameliorates β cell function and rebalances Th17/Treg cells in NOD mice
    Min Chen
    Qianhui Zhang
    Yanhong Wei
    Qianqian Wan
    Min Xu
    Xiaoqi Chen
    Endocrine, 2022, 76 : 44 - 52
  • [32] LOW-DOSE ULTRAVIOLET-B IRRADIATION DEPLETES HUMAN EPIDERMAL LANGERHANS CELLS
    MURPHY, GM
    NORRIS, PG
    YOUNG, AR
    CORBETT, MF
    HAWK, JLM
    BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (06) : 674 - 677
  • [33] MAb Therapy:: the use of anti-CD20 Abs -: In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs
    Derigs, HG
    CYTOTHERAPY, 2000, 2 (06) : 445 - 453
  • [34] B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
    Shaw, T
    Quan, J
    Totoritis, MC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 55 - 59
  • [35] Switching from intravenous to subcutaneous anti-CD20 mediated B cell depletion preserves memory B cells in patients with RRMS
    Haase, Stefanie
    Burner, Felix
    Freudenstein, David
    Angstwurm, Klemens
    Lee, De-Hyung
    Linker, Ralf
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 621 - 622
  • [36] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [37] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [38] Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
    Liebman, Howard A.
    Saleh, Mansoor N.
    Bussel, James B.
    Negrea, Ovidiu George
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) : 693 - 701
  • [39] Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies
    Allen, S. L.
    Rai, K. R.
    Elstrom, R.
    Negrea, O. G.
    Farber, C. M.
    Abbasi, R.
    Teoh, N.
    Horne, H.
    Wegener, W. A.
    Goldenberg, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Pax-5 demonstrates residual B-cells in bone marrow trephines post anti-CD20 immunotherapy.
    D'Souza, A
    Juneja, S
    Trivett, M
    Carney, D
    Westerman, D
    BLOOD, 2005, 106 (11) : 335B - 335B
12345